within Pharmacolibrary.Drugs.ATC.N;

model N02CD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.1666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 140 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0038599999999999997,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0016200000000000001,
    k12             = 0.884,
    k21             = 0.884
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CD01</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It is approved for the preventive treatment of migraine in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following subcutaneous administration.</p><h4>References</h4><ol><li><p>Shen, Q, et al., &amp; Wang, Z (2022). Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 42(7) 623–630. DOI:<a href=\"https://doi.org/10.1007/s40261-022-01171-5\">10.1007/s40261-022-01171-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35727536/\">https://pubmed.ncbi.nlm.nih.gov/35727536</a></p></li><li><p>Shen, Q, et al., &amp; Wang, Z (2023). Correction: Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 43(12) 973–974. DOI:<a href=\"https://doi.org/10.1007/s40261-023-01321-3\">10.1007/s40261-023-01321-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37991687/\">https://pubmed.ncbi.nlm.nih.gov/37991687</a></p></li><li><p>Bussiere, JL, et al., &amp; Monticello, TM (2019). Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. <i>Regulatory toxicology and pharmacology : RTP</i> 106 224–238. DOI:<a href=\"https://doi.org/10.1016/j.yrtph.2019.05.013\">10.1016/j.yrtph.2019.05.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31085251/\">https://pubmed.ncbi.nlm.nih.gov/31085251</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CD01;
